메뉴 건너뛰기




Volumn 58, Issue 1, 2013, Pages 388-396

High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury

Author keywords

[No Author keywords available]

Indexed keywords

ALPIDEM; BENOXAPROFEN; BROMFENAC; DICLOFENAC; ENTACAPONE; IBUPROFEN; MOXIFLOXACIN; NON PRESCRIPTION DRUG; OCTANOL; TOLCAPONE; TROVAFLOXACIN; WATER; ZOLPIDEM;

EID: 84879605416     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26208     Document Type: Article
Times cited : (291)

References (33)
  • 1
    • 34548188788 scopus 로고    scopus 로고
    • Drug hepatotoxicity from a regulatory perspective
    • Senior JR. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis 2007; 11: 507-524.
    • (2007) Clin Liver Dis , vol.11 , pp. 507-524
    • Senior, J.R.1
  • 2
    • 0034424966 scopus 로고    scopus 로고
    • Drug-induced liver disease
    • Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis 2000; 4: 73-96.
    • (2000) Clin Liver Dis , vol.4 , pp. 73-96
    • Zimmerman, H.J.1
  • 3
    • 0037126649 scopus 로고    scopus 로고
    • Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States
    • Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954.
    • (2002) Ann Intern Med , vol.137 , pp. 947-954
    • Ostapowicz, G.1    Fontana, R.J.2    Schiodt, F.V.3    Larson, A.4    Davern, T.J.5    Han, S.H.6
  • 4
    • 41349087120 scopus 로고    scopus 로고
    • The role of early in vivo toxicity testing in drug discovery toxicology
    • Fielden MR, Kolaja KL. The role of early in vivo toxicity testing in drug discovery toxicology. Expert Opin Drug Saf 2008; 7: 107-110.
    • (2008) Expert Opin Drug Saf , vol.7 , pp. 107-110
    • Fielden, M.R.1    Kolaja, K.L.2
  • 5
    • 84862932616 scopus 로고    scopus 로고
    • Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans?
    • Zhang M, Chen M, Tong W. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans? Chem Res Toxicol 2012; 25: 122-129.
    • (2012) Chem Res Toxicol , vol.25 , pp. 122-129
    • Zhang, M.1    Chen, M.2    Tong, W.3
  • 7
    • 77955341032 scopus 로고    scopus 로고
    • Back to basics for idiosyncratic drug-induced liver injury: dose and metabolism make the poison
    • Ballet F. Back to basics for idiosyncratic drug-induced liver injury: dose and metabolism make the poison. Gastroenterol Clin Biol 2010; 34: 348-350.
    • (2010) Gastroenterol Clin Biol , vol.34 , pp. 348-350
    • Ballet, F.1
  • 8
    • 18844373318 scopus 로고    scopus 로고
    • Role of metabolism in drug-induced idiosyncratic hepatotoxicity
    • Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005; 35: 325-361.
    • (2005) Crit Rev Toxicol , vol.35 , pp. 325-361
    • Walgren, J.L.1    Mitchell, M.D.2    Thompson, D.C.3
  • 9
    • 46249118651 scopus 로고    scopus 로고
    • Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals
    • Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. HEPATOLOGY 2008; 47: 2003-2009.
    • (2008) HEPATOLOGY , vol.47 , pp. 2003-2009
    • Lammert, C.1    Einarsson, S.2    Saha, C.3    Niklasson, A.4    Bjornsson, E.5    Chalasani, N.6
  • 10
    • 75449112589 scopus 로고    scopus 로고
    • Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events
    • Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. HEPATOLOGY 2010; 51: 615-620.
    • (2010) HEPATOLOGY , vol.51 , pp. 615-620
    • Lammert, C.1    Bjornsson, E.2    Niklasson, A.3    Chalasani, N.4
  • 11
    • 0035147506 scopus 로고    scopus 로고
    • Prediction of a new drug's potential to cause idiosyncratic reactions
    • Uetrecht J. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Discov Devel 2001; 4: 55-59.
    • (2001) Curr Opin Drug Discov Devel , vol.4 , pp. 55-59
    • Uetrecht, J.1
  • 12
    • 35748934487 scopus 로고    scopus 로고
    • The influence of drug-like concepts on decision-making in medicinal chemistry
    • Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007; 6: 881-890.
    • (2007) Nat Rev Drug Discov , vol.6 , pp. 881-890
    • Leeson, P.D.1    Springthorpe, B.2
  • 13
    • 77749315417 scopus 로고    scopus 로고
    • Lipophilicity in drug discovery
    • Waring MJ. Lipophilicity in drug discovery. Expert Opin Drug Discovery 2010; 5: 235-248.
    • (2010) Expert Opin Drug Discovery , vol.5 , pp. 235-248
    • Waring, M.J.1
  • 15
    • 65549132575 scopus 로고    scopus 로고
    • Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds
    • Peters JU, Schnider P, Mattei P, Kansy M. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem 2009; 4: 680-686.
    • (2009) ChemMedChem , vol.4 , pp. 680-686
    • Peters, J.U.1    Schnider, P.2    Mattei, P.3    Kansy, M.4
  • 16
    • 65449179589 scopus 로고    scopus 로고
    • Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability
    • Waring MJ. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. Bioorg Med Chem Lett 2009; 19: 2844-2851.
    • (2009) Bioorg Med Chem Lett , vol.19 , pp. 2844-2851
    • Waring, M.J.1
  • 17
    • 80051665573 scopus 로고    scopus 로고
    • FDA-approved drug labeling for the study of drug-induced liver injury
    • Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 2011; 16: 697-703.
    • (2011) Drug Discov Today , vol.16 , pp. 697-703
    • Chen, M.1    Vijay, V.2    Shi, Q.3    Liu, Z.4    Fang, H.5    Tong, W.6
  • 18
    • 84879601164 scopus 로고    scopus 로고
    • US Food and Drug Administration. Liver Toxicity Knowledge Base (LTKB). Accessed October 30
    • US Food and Drug Administration. Liver Toxicity Knowledge Base (LTKB). http://www.fda.gov/ScienceResearch/BioinformaticsTools/LiverToxicityKnowledgeBase/ucm2024036.htm. Accessed October 30, 2012.
    • (2012)
  • 20
    • 84879606847 scopus 로고    scopus 로고
    • R Foundation for Statistical Computing. R: a language and environment for statistical computing. Accessed October 30, 2012.
    • R Foundation for Statistical Computing. R: a language and environment for statistical computing. http://www.R-project.org/2011, Accessed October 30, 2012.
  • 22
    • 84869462906 scopus 로고    scopus 로고
    • A decade of toxicogenomic research and its contribution to toxicological science
    • Chen M, Zhang M, Borlak J, Tong W. A decade of toxicogenomic research and its contribution to toxicological science. Toxicol Sci 2012; 130: 217-228.
    • (2012) Toxicol Sci , vol.130 , pp. 217-228
    • Chen, M.1    Zhang, M.2    Borlak, J.3    Tong, W.4
  • 23
    • 84879602893 scopus 로고    scopus 로고
    • National Center for Toxicological Research. LTBS: Liver Toxicity Biomarker Study.Accessed October 30
    • National Center for Toxicological Research. LTBS: Liver Toxicity Biomarker Study. http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm079290.pdf Accessed October 30, 2012.
    • (2012)
  • 25
    • 68149160053 scopus 로고    scopus 로고
    • Physicochemical drug properties associated with in vivo toxicological outcomes: a review
    • Price DA, Blagg J, Jones L, Greene N, Wager T. Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Expert Opin Drug Metab Toxicol 2009; 5: 921-931.
    • (2009) Expert Opin Drug Metab Toxicol , vol.5 , pp. 921-931
    • Price, D.A.1    Blagg, J.2    Jones, L.3    Greene, N.4    Wager, T.5
  • 27
    • 77952718055 scopus 로고    scopus 로고
    • Risk factors for idiosyncratic drug-induced liver injury
    • Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010; 138: 2246-2259.
    • (2010) Gastroenterology , vol.138 , pp. 2246-2259
    • Chalasani, N.1    Bjornsson, E.2
  • 28
    • 33845874637 scopus 로고    scopus 로고
    • Drug treatments for obesity: orlistat, sibutramine, and rimonabant
    • Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71-77.
    • (2007) Lancet , vol.369 , pp. 71-77
    • Padwal, R.S.1    Majumdar, S.R.2
  • 29
    • 84879607140 scopus 로고    scopus 로고
    • US Food and Drug Administration. FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. Accessed October 30
    • US Food and Drug Administration. FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm. Accessed October 30, 2012.
    • (2012)
  • 30
    • 0029090947 scopus 로고
    • Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions
    • Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. HEPATOLOGY 1995; 22: 820-827.
    • (1995) HEPATOLOGY , vol.22 , pp. 820-827
    • Banks, A.T.1    Zimmerman, H.J.2    Ishak, K.G.3    Harter, J.G.4
  • 31
    • 0032173110 scopus 로고    scopus 로고
    • Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series
    • Riley TR 3rd, Smith JP. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am J Gastroenterol 1998; 93: 1563-1565.
    • (1998) Am J Gastroenterol , vol.93 , pp. 1563-1565
    • Riley, T.R.1    Smith, J.P.2
  • 32
    • 69949092077 scopus 로고    scopus 로고
    • 3.3 Trovafloxacin: a case study of idiosyncratic or iatrogenic liver toxicity-molecular mechanisms and lessons for pharmacotoxicity
    • Borlak J. 3.3 Trovafloxacin: a case study of idiosyncratic or iatrogenic liver toxicity-molecular mechanisms and lessons for pharmacotoxicity. Hum Exp Toxicol 2009; 28: 119-121.
    • (2009) Hum Exp Toxicol , vol.28 , pp. 119-121
    • Borlak, J.1
  • 33
    • 35848933222 scopus 로고    scopus 로고
    • Mechanisms of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system
    • Sun Q, Zhu R, Foss FW Jr, Macdonald TL. Mechanisms of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system. Bioorg Med Chem Lett 2007; 17: 6682-6686.
    • (2007) Bioorg Med Chem Lett , vol.17 , pp. 6682-6686
    • Sun, Q.1    Zhu, R.2    Foss Jr, F.W.3    Macdonald, T.L.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.